Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Eukaryotic Gene Expression
Facteur d'impact: 1.841 Facteur d'impact sur 5 ans: 1.927 SJR: 0.627 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimer: 1045-4403
ISSN En ligne: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v8.i3-4.50
pages 321-356

The Development of Monoclonal Antibodies for the Therapy of Cancer

Roula A. Farah
The Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, Texas 75235-8576
Birgitta Clinchy
The Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, Texas 75235-8576
Larry Herrera
The Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, Texas 75235-8576
Ellen S. Vitetta
The Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, Texas 75235-8576

RÉSUMÉ

Monoclonal antibodies (Mabs) were first decribed by Kohler and Milstein in 1975. Not only did this discovery lead to a Nobel prize, but it created an enormous scientific field that has now become a multimillion dollar industry. Mabs made the transition from laboratory reagents to clinical diagnostics very quickly. However, their development as therapeutic agents was, as predicted, more costly and time-consuming. Indeed, clinicians and scientists were required to learn a new set of rules for using these large, immunogenic, targeted agents in humans. Nevertheless, in 1997 the first Mab was licensed in the U.S. and several others will soon follow. In this review, we discuss Mab-based strategies for the treatment of cancer. We compare native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. The rationale for their development, their advantages, their in vitro and in vivo performance, and their clinical usefulness are discussed.


Articles with similar content:

Bacterial Toxins in Cancer Immunotherapy
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 3-4
Lenka Sadilkova, Irena Adkins, Lenka Palova-Jelinkova
Gene Therapy: Basic Concepts and Recent Advances
Critical Reviews™ in Eukaryotic Gene Expression, Vol.6, 1996, issue 1
Deborah L. Sokol , Alan M. Gewirtz
Adoptive Immunotherapy of Cancer Using Chimeric Antigen Receptor−Engineered T Cells
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
John Maher, Daniela Achkova
Biological Role of Cell-Free Nucleic Acids in Cancer: The Theory of Genometastasis
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 1 - 2
Damian Garcia-Olmo , Dolores C. Garcia-Olmo
Nanotechnology-Based Photodynamic Therapy: Concepts, Advances, and Perspectives
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 5
Nitin K. Jain, Goutam Rath, Tarun Garg, Amit Kumar Goyal